ARCHIMED Completes Acquisition of Microfluidics Unit
The former Standard BioTools microfluidics business now operates independently as Biomark Scientific.
Updated on Nov. 3, 2026 in Biotech
Live Poll
Do you trust private equity firms to keep up quality when they buy science companies?
ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics Business, which will operate as a standalone company named Biomark Scientific. The business retains its dedicated team and is supported by enhanced capabilities from ARCHIMED.
Why it matters
The deal moves a microfluidics tools provider, previously part of Fluidigm, under the ownership of a healthcare-focused private equity firm. Biomark Scientific plans to build on its established technology and customer relationships while expanding its capabilities.
The transaction is documented through an official announcement, with ARCHIMED managing €15 billion across its funds and the business tracing its roots to Fluidigm, founded in 1999. The financial terms of the deal and the company's post-acquisition revenue were not disclosed in the source information.
The players
ARCHIMED
ARCHIMED is a European private equity firm focused on healthcare investments, managing €15 billion across its funds and operating offices in Europe, North America and Asia.
Standard BioTools
Standard BioTools is a life sciences tools company formerly known as Fluidigm, which renamed itself in 2022 and sold its microfluidics business to ARCHIMED.
Biomark Scientific
Biomark Scientific is the standalone company that now operates the former Standard BioTools microfluidics business, providing high-throughput genomics and multi-assay systems.
The details
ARCHIMED, a healthcare-focused private equity firm, completed its acquisition of Standard BioTools' Microfluidics Business on November 3, 2026. The Biomark X9 system, an automated PCR, qPCR and NGS library prep platform, is among the technologies the business offers for high-throughput and multi-assay genomics.
Timeline
2022: Fluidigm was renamed Standard BioTools.
March 16, 2026: Standard BioTools filed its Form 10-K with the SEC.
October 21, 2026: The Form S-4 registration statement was declared effective by the SEC.
November 3, 2026: ARCHIMED completed the acquisition and the business was renamed Biomark Scientific.
Market Landscape
The divestiture reflects a broader pattern of life sciences tools companies reshaping their portfolios through carve-outs, with the microfluidics line previously sitting inside the Fluidigm and Standard BioTools corporate structure. Private equity ownership of specialized genomics tools providers positions the business to pursue growth separate from its former parent.
For researchers and laboratories that rely on PCR, qPCR and NGS library prep systems, the ownership change may affect the vendor relationship and product support going forward. Customers using existing Biomark systems should look for communications from Biomark Scientific regarding service and product continuity.
The takeaway
Ownership changes in specialized lab tools can reshape product roadmaps and customer support, so laboratories should confirm service terms with their vendor. Watching how Biomark Scientific expands its capabilities under new ownership will indicate the direction of the business.
Further reading
Explore more biotech developments shaping the life sciences tools industry.
More information
Review the official filings and announcements on the Standard BioTools investor relations website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust private equity firms to keep up quality when they buy science companies?
